Continuous subcutaneous infusion of beta 2-agonists in infantile asthma.
Eleven infants presenting with an asthmatic syndrome were treated with subcutaneous infusions of a beta 2-agonist (beta 2A) during an acute episode. This treatment was used after difficulties with or failure of beta 2A infusions and IV nebulizations. No local or general adverse reactions were observed. The serum concentrations of salbutamol obtained at a dose of 0.1 micrograms/kg/min were measured in six infants and found to be within the generally accepted therapeutic range. This mode of administration proved extremely useful, both by itself and as part of a therapeutic protocol, combined with an antibiotic, a corticosteroid, and theophylline. It avoids the difficulties of administering beta 2A intravenously or by nebulization, while preserving some degree of freedom and better general care for the child. The preferred indication is in treatment of severe acute asthmatic episodes after failure of nebulizations. The exact place in the therapeutic arsenal of infantile asthma remains to be defined.
Unité des Maladies Respiratoires de l'Enfant et de l'Adolescent, Toulouse, France.
F
F
Brémont
V
V
Moisan
G
G
Dutau
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage* / Q000627:therapeutic use; D000420:Albuterol / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D005240:Feasibility Studies; D006801:Humans; D007223:Infant; D007260:Infusion Pumps; D007279:Injections, Subcutaneous; D010865:Pilot Projects; D013726:Terbutaline / Q000008:administration & dosage* / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D013726:Terbutaline; D000420:Albuterol